Cargando…

Beta-blockers in liver cirrhosis

Since the original description of the effectiveness of β-blockers in lowering the portal pressure and therefore the risk of variceal bleeding, more than 500 articles in the English literature on the use of non selective β-blockers (NSBB) in cirrhosis have been published. The use of NSBB in pre-prima...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giannelli, Valerio, Lattanzi, Barbara, Thalheimer, Ulrich, Merli, Manuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hellenic Society of Gastroenterology 2014
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959530/ https://www.ncbi.nlm.nih.gov/pubmed/24714633

Ejemplares similares

Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
por: Sauerbruch, Tilman, et al.
Publicado: (2023)

The Effects of 12-Week Beta-Hydroxy-Beta-Methylbutyrate Supplementation in Patients with Liver Cirrhosis: Results from a Randomized Controlled Single-Blind Pilot Study
por: Lattanzi, Barbara, et al.
Publicado: (2021)

Cardiovascular dysfunction in patients with liver cirrhosis
por: Fede, Giuseppe, et al.
Publicado: (2015)

Beta-blockers in cirrhosis: Evidence-based indications and limitations
por: Rodrigues, Susana G., et al.
Publicado: (2019)

The Spread of Multi Drug Resistant Infections Is Leading to an Increase in the Empirical Antibiotic Treatment Failure in Cirrhosis: A Prospective Survey
por: Merli, Manuela, et al.
Publicado: (2015)

Beta-blocker therapy in pediatric heart failure: 50 years lost to improve pharmacotherapy of a deadly disease
por: Buchhorn, Reiner
Publicado: (2021)

Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity?
por: Nabilou, Puria, et al.
Publicado: (2022)

C-reactive protein and bacterial infection in cirrhosis
por: Pieri, Giulia, et al.
Publicado: (2014)

Antimicrobial prophylaxis in decompensated cirrhosis: friend or foe?
por: Crocombe, Dominic, et al.
Publicado: (2023)

Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis
por: Sinakos, Emmanouil, et al.
Publicado: (2022)

Nutrition in Liver Cirrhosis and Transplantation—Current State and Knowledge Gaps
por: Raman, Maitreyi, et al.
Publicado: (2020)

Beta Blockers and Melanoma
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Beta-catenin in disease
por: Prakash, Sharada, et al.
Publicado: (2016)

Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation
por: Ngwa, Taiwo, et al.
Publicado: (2020)

Sarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt
por: Praktiknjo, Michael, et al.
Publicado: (2019)

The Impact of Transjugular Intrahepatic Portosystemic Shunt on Nutrition in Liver Cirrhosis Patients: A Systematic Review
por: Gazda, Jakub, et al.
Publicado: (2023)

Nonselective beta-blocker use is associated with increased hepatic encephalopathy-related readmissions in cirrhosis
por: Fallahzadeh, Mohammad Amin, et al.
Publicado: (2022)

Perioperative use of beta-blockers
por: Priebe, Hans-Joachim
Publicado: (2009)

Exploration on the Effect of Nonselective β-Receptor Blockers (NSBBs) on Hemodynamic Parameters in Complicated Liver Cirrhosis
por: Mao, Gang, et al.
Publicado: (2022)

Beta-blockers: friend or foe in asthma?
por: Arboe, Bente, et al.
Publicado: (2013)

Beta-Blockers and Cancer: Where Are We?
por: Peixoto, Rita, et al.
Publicado: (2020)

Neuropsychiatric Consequences of Lipophilic Beta-Blockers
por: Cojocariu, Sabina Alexandra, et al.
Publicado: (2021)

Beta secretase activity in peripheral nerve regeneration
por: Tallon, Carolyn, et al.
Publicado: (2017)

Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis
por: He, Xinyi, et al.
Publicado: (2023)

β-blockers in advanced cirrhosis: More friend than enemy
por: Yoon, Ki Tae, et al.
Publicado: (2021)

Topical beta‐blockers in dermatologic therapy
por: Filoni, Angela, et al.
Publicado: (2021)

Treatment with non‐selective beta‐blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis
por: Gimenez, Paula, et al.
Publicado: (2018)

Beta-blockers in septic shock: What is new?
por: Lescroart, Mickael, et al.
Publicado: (2022)

Transforming growth factor beta 1, a cytokine with regenerative functions
por: Sulaiman, Wale, et al.
Publicado: (2016)

Beta‐blockers for hypertension
por: Wiysonge, Charles S, et al.
Publicado: (2017)

Beta-blockers in sepsis
por: Singer, Mervyn
Publicado: (2019)

Beta-adrenergic signaling on neuroendocrine differentiation, angiogenesis, and metastasis in prostate cancer progression
por: Zhao, Yicheng, et al.
Publicado: (2019)

Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis
por: Matsui, Osamu, et al.
Publicado: (2011)

An unusual toxicity with beta blocker and calcium channel blocker
por: Anand, Vijay, et al.
Publicado: (2015)

Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?
por: Kim, Tae Wan, et al.
Publicado: (2012)

The complexities underlying age-related macular degeneration: could amyloid beta play an important role?
por: Lynn, Savannah A., et al.
Publicado: (2017)

Islet autoimmunity in human type 1 diabetes: initiation and progression from the perspective of the beta cell
por: Thompson, Peter J., et al.
Publicado: (2023)

Beta-Blockers and Oxidative Stress in Patients with Heart Failure
por: Nakamura, Kazufumi, et al.
Publicado: (2011)

Current Knowledge of Beta-Blockers in Chronic Hemodialysis Patients
por: Haddiya, Intissar, et al.
Publicado: (2023)

Beta-blockers and physical frailty in patients with end-stage liver disease
por: Kuo, Selena Z, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_23b171h6k17r380autaef4jpnt